Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children - Archive ouverte HAL Access content directly
Journal Articles RMD Open : Rheumatic & Musculoskeletal Diseases Year : 2016

Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children

Abstract

Arthritis is one of the main manifestations of mixed connective tissue disease (MCTD) and overlap syndrome in children and can be responsible for functional disability. We report on 2 children with arthritis that were dramatically improved by a treatment with interleukin-6 (IL-6) blockers in the context of connective tissue disease. However, in both cases, other systemic autoimmune symptoms were not modified by the treatment and autoantibodies tend to increase, suggesting a differential effect of IL-6 inhibition on articular inflammation and systemic autoimmunity.
Fichier principal
Vignette du fichier
e000271.full.pdf (2 Mo) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-01911117 , version 1 (20-02-2024)

Identifiers

Cite

Natalia Cabrera, Agnes Duquesne, Marine Desjonquères, Jean-Paul Larbre, Jean-Christophe Lega, et al.. Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children. RMD Open : Rheumatic & Musculoskeletal Diseases, 2016, 2 (2), pp.e000271. ⟨10.1136/rmdopen-2016-000271⟩. ⟨hal-01911117⟩
69 View
6 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More